Breaking News

Karyopharm Awarded MS Research Grant

By Kristin Brooks | January 8, 2014

To evaluate the potential of SINE compounds in inflammatory disease

Karyopharm Therapeutics Inc. has been awarded a grant from the National Multiple Sclerosis (MS) Society through its affiliate, Fast Forward, to support research on the potential of SINE compounds in inflammatory disease, including MS.
 
SINE compounds inhibit Exportin-1 (XPO1 or CRM1), which mediates the export of mammalian cargo proteins. In MS, toxic factors accumulate in the brain and spinal cord that may attack or destroy the myelin coating on a neuron's axon leading to neurodegenerative symptoms. Preclinical data suggest that SINE compounds may reduce inflammation and protect against these toxic factors in neurons.
 
"We are very excited about our continuing collaboration with the National MS Society, and with Mount Sinai with Dr. Patrizia Casaccia, who has dedicated herself to advancing research in MS and other important diseases," said Karyopharm founder, chief scientific officer, and president, Sharon Shacham, Ph.D., M.B.A. "We believe SINE compounds may offer significant therapeutic benefits in a range of indications and look forward to exploring the potential application of SINE compounds in inflammatory diseases, including MS."

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research